Reiterate PerkinElmer at Neutral - Analyst Blog

By
A A A

On Feb 7, we retained PerkinElmer ( PKI ) at Neutral after the company met Zacks Consensus Estimate for earnings but missed revenue estimate for fourth quarter 2012.

Why the Retention?

PerkinElmer released its results for the fourth quarter 2012 on Jan 31. The company posted adjusted earnings of 65 cents per share, meeting the Zacks Consensus Estimate and surpassing the year-ago earnings of 62 cents a share. Revenues in the reported quarter increased 6.2% year over year to $572.9 million, missing the Zacks Consensus Estimate of $580 million.

Over the past 30 days, the Zacks Consensus Estimate for 2013 has moved down by a penny to $2.30 while the same for 2014 has dropped by 3 cents to $2.58 during the same timeframe.

The company forecasts adjusted earnings per share for 2013 in the range of $2.24 to $2.32. Reported earnings per share from continuing operations are forecast in the range of $1.57 to $1.65. Organic revenue is expected to increase in the mid-single digits.

PerkinElmer has established itself as a market leader, particularly in the genetic screening segment, and holds one of top two market share positions in several important subsets of the life sciences technology and genetic screening businesses.

The company continues to execute well across several product lines aided by rebounding markets and cost containment efforts. PerkinElmer's transfer of select manufacturing to China has expanded its operating margins. The company has increased its productivity and improved product mix in favor of higher value added products, resulting in higher operating margins.

PerkinElmer, however, operates in a highly competitive industry characterized by rapid technological change and evolving industry standards. As a result, the company must make large investments in R&D in order to retain a competitive pipeline. PerkinElmer competes with Thermo Fisher Scientific ( TMO ) among others.

PerkinElmer's exposure to poor end market visibility might result in a relatively unattractive risk-reward trade-off for the stock. However, the company's operations, both sales and manufacturing, are diversified on a geographic basis. It has emerged as a higher-growth, higher-margin company vis-à-vis its peers.

Other Stocks to Consider

We currently have a Zacks Rank #3 (Hold) on PerkinElmer. Mettler-Toledo International Inc. ( MTD ) and Becton Dickinson and Company ( BDX ) carry Zacks Rank #2 (Buy).  Both stocks are expected to do well.



BECTON DICKINSO (BDX): Free Stock Analysis Report

METTLER-TOLEDO (MTD): Free Stock Analysis Report

PERKINELMER INC (PKI): Free Stock Analysis Report

THERMO FISHER (TMO): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: Investing , Business , Stocks

Referenced Stocks: BDX , MTD , PKI , TMO

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Your Car Is Spying on You
Your Car Is Spying on You           

Stocks

Referenced

Most Active by Volume

73,078,214
  • $30.33 ▼ 3.90%
57,046,796
  • $15.52 ▲ 0.45%
51,290,831
  • $100.57 ▲ 0.04%
39,855,468
  • $8.13 ▲ 1.37%
31,693,544
  • $5.50 ▲ 20.35%
31,532,510
  • $10.33 ▲ 0.78%
31,526,753
  • $39.10 ▲ 47.21%
28,366,542
  • $26.36 ▲ 1.19%
As of 8/20/2014, 04:04 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com